Subscribe to thousands of academic journals for just $40/month
Read and share the articles you need for your research, all in one place.

Capecitabine as third line therapy in patients with advanced colorectal cancer1

Acta Oncologica , Volume 44 (3) – May 1, 2005

Details

Publisher
Informa UK Ltd
Copyright
© 2005 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted
Subject
Original Article
ISSN
0284-186X
eISSN
1651-226X
D.O.I.
10.1080/02841860510029662
Publisher site
See Article on Publisher Site

Preview Only

Expand Tray Hide Tray

Capecitabine as third line therapy in patients with advanced colorectal cancer1

Abstract

This study sought to determine whether third line therapy with capecitabine (cap.) could provide any clinical benefit in patients with advanced colorectal cancer who have progressed on 5-Fu combination therapy with both irinotecan and oxaliplatin. Twenty patients who were pretreated with and had progressed on irinotecan+Nordic FLv (5-Fu/leukovorin) and oxaliplatin+c.i. 5-Fu/leukovorin were studied. Cap. was administered at 1000–1250 mg/m 2 bid d1-14 q 3 w. Time to progression (TTP) (either radiological or clinical) and overall survival (OS) were estimated with the Kaplan-Meier actuarial method. The median number of administered cap. courses was four. No radiological or biochemical responses were observed. Three patients were classified as having stable disease at three months. Two of these patients had, however, minor radiological progression and a ≥100% increase in CEA compared to base line. Seventeen patients were classified as having progressive disease during the first three months period. Median TTP and OS were 2.8 months and 6.1 months, respectively. A response rate of ≥15% for third line cap. in metastatic CRC can be ruled out. Median PFS was limited in the study population. This observation and the few cases with SD at three months, lead us to believe that little or no clinical benefit can be expected from single drug cap. in patients with irinotecan- and oxaliplatin-combination resistant advanced colorectal cancer.
Loading next page...

Preview Only. This article cannot be rented because we do not currently have permission from the publisher.

 
/lp/informa-healthcare/capecitabine-as-third-line-therapy-in-patients-with-advanced-0B2cVV0kRO